ACHV missed EPS expectations by 5.80%

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company based in Seattle, is developing cytisinicline, a plant-based alkaloid aimed at aiding smoking cessation through its dual-acting mechanism as both an agonist and antagonist. Cytisinicline targets the alpha-4 beta-2 nicotinic acetylcholine receptors in the brain to alleviate nicotine cravings and withdrawal symptoms, positioning it as a potential improvement over current prescription and OTC cessation aids.